Scarica l'app Stockscreener
1.04
2.97%
0.03
Dopo l'orario di chiusura:
1.02
-0.02
-1.92%
Precedente Chiudi:
$1.01
Aprire:
$1.01
Volume 24 ore:
381.36K
Relative Volume:
0.35
Capitalizzazione di mercato:
$13.32M
Reddito:
-
Utile/perdita netta:
$-11.90M
Rapporto P/E:
-0.00505
EPS:
-206.0125
Flusso di cassa netto:
$-12.75M
1 W Prestazione:
-0.95%
1M Prestazione:
+20.02%
6M Prestazione:
-11.11%
1 anno Prestazione:
+358.96%
Intervallo 1D:
$0.96
$1.04
Intervallo di 1 settimana:
$0.9256
$1.0899
Portata 52W:
$0.1131
$3.95
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Nome
Allarity Therapeutics Inc
Settore
Industria
Telefono
401-426-4664
Indirizzo
24 SCHOOL ST., 2ND FLOOR, BOSTON
Confronta ALLR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.04 | 13.32M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Allarity Therapeutics Inc Borsa (ALLR) Ultime notizie
Allarity Therapeutics Holds Annual Stockholders Meeting - TipRanks
Allarity Therapeutics Stock Nears Yearly Low: A Trader’s High-Risk Analysis - thekhabrilal
Allarity Therapeutics, Inc Announces Changes to Board of Directors - MarketScreener
Allarity Therapeutics appoints pharma veteran Høiland to board By Investing.com - Investing.com India
Allarity Therapeutics Appoints Jesper Høiland to Board - TipRanks
Allarity Therapeutics Announces Changes To Board Of Directors - MarketScreener
Allarity Therapeutics appoints pharma veteran Høiland to board - Investing.com
Allarity Therapeutics Announces Changes to Board of Directors - GlobeNewswire
Pharma Veteran Jesper Høiland Brings 30 Years Experience to Allarity Board Amid Clinical Momentum - Stock Titan
Allarity Therapeutics (NASDAQ:ALLR) Shares Up 4.2% – Here’s Why - Defense World
Wolf Haldenstein Adler Freeman & Herz LLP Announces that it is Investigating Allarity Therapeutics, Inc. for Potential Violations of Federal Securities Laws - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation - ACCESS Newswire
Allarity Therapeutics Partners with Indiana Biosciences - TipRanks
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - Defense World
Allarity Therapeutics partners with IBRI on cancer drug research By Investing.com - Investing.com South Africa
Allarity Teams With IBRI To Advance Dual-Action Cancer Drug Stenoparib - Nasdaq
Allarity Therapeutics partners with IBRI on cancer drug research - Investing.com Australia
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Advance Understanding of Stenoparib's Mechanism of Action - Nasdaq
Allarity Therapeutics Announces Research Collaboration with - GlobeNewswire
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action - Yahoo
Allarity Therapeutics Launches Phase 2 Trial for Stenoparib - TipRanks
Allarity Therapeutics Announces First Patient Enrolled in - GlobeNewswire
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer - The Manila Times
Allarity Therapeutics Enrolls First Patient in Phase 2 Trial of Stenoparib for Advanced Ovarian Cancer - Nasdaq
Revolutionary Ovarian Cancer Drug Begins Phase 2 Trial: Could Replace Traditional Chemotherapy - Stock Titan
ALLR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Allarity Therapeutics, Inc. - ACCESS Newswire
Allarity Therapeutics (NASDAQ:ALLR) Stock Rating Upgraded by Wall Street Zen - Defense World
Allarity Therapeutics CEO to Present at Pharma Summit - TipRanks
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US - GlobeNewswire
Metrics That Matter About Allarity Therapeutics Inc (NASDAQ: ALLR) - Stocksregister
Allarity Therapeutics Reports Positive Clinical Updates and Financial Highlights for Q1 2025 - Nasdaq
Allarity Therapeutics Provides First Quarter 2025 Update, - GlobeNewswire
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment - Stock Titan
You might want to take a look at Allarity Therapeutics Inc (ALLR) now - Sete News
Was anything positive for Allarity Therapeutics Inc (ALLR) stock last session? - uspostnews.com
The Psychology of Allarity Therapeutics Inc Inc. (ALLR) Price Performance: Understanding Market Sentiment - investchronicle.com
Upward Trajectory: Allarity Therapeutics Inc (ALLR) Posts a Slidee, Closing at 1.07 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Allarity unveils new multiple myeloma treatment predictor - Investing.com
Allarity unveils new multiple myeloma treatment predictor By Investing.com - Investing.com South Africa
Healthy Upside Potential: Allarity Therapeutics Inc (ALLR) - Sete News
Allarity Therapeutics Presents Novel Drug Response - GlobeNewswire
Novel AI Predictor Identifies Multiple Myeloma Patients for Targeted Treatment | ALLR Stock News - Stock Titan
Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX
Allarity Therapeutics Inc Azioni (ALLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):